The Technical Analyst
Cue Biopharma Inc [CUE]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Cue Biopharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.53% $1.540
America/New_York / 19 apr 2024 @ 13:52
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 74.91 mill |
| EPS: | -1.110 |
| P/E: | -1.390 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 48.64 mill |
| Avg Daily Volume: | 0.258 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.390 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.24x |
| Company: PE -1.390 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.384 - 1.696 ( +/- 10.13%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-06 | Sandercock Colin | Buy | 175 000 | Stock Option (right to buy) |
| 2024-03-06 | Suri Anish | Buy | 300 000 | Stock Option (right to buy) |
| 2024-03-06 | Millar Kerri-ann | Buy | 250 000 | Stock Option (right to buy) |
| 2024-03-06 | Passeri Daniel R | Buy | 400 000 | Stock Option (right to buy) |
| 2024-03-06 | Levisetti Matteo | Buy | 260 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 97.88 |
| Last 98 transactions |
| Buy: 5 498 246 | Sell: 593 660 |
Forecast:
15:31 - $1.546
Live Trading Signals (every 1 min)
Forecast
1: 14:01 - $1.544
Forecast 2: 14:51 - $1.551
Forecast 3: 15:31 - $1.546
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.540 (-2.53% ) |
| Volume | 0.0856 mill |
| Avg. Vol. | 0.258 mill |
| % of Avg. Vol | 33.20 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CUE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CUE
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-08 16:05:00 - Press Release
Cue Biopharma reports Fourth Quarter And Full Year 2023 Financial Results And updated Business Highlights
Boston, april 08, 2024 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific t cells, today reported fourth quarter and full year 2023 financial results.
2024-02-29 10:00:00 - Press Release
Cue Biopharma's Lead Clinical Asset, Cue-101, To Be Featured At The 2024 Multi-disciplinary Head And Neck Cancers Symposium
Boston, feb. 29, 2024 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific t cells, announced today that the company's lead clinical asset, cue-101, will be featured in a presentation at the 2024 multi-disciplinary head and neck cancers symposium given by alexander dimitrios colevas, m.d., a principal investigator at stanford university participating in the cue-101 clinical trial. the symposium is being held in phoenix, arizona and virtually from february 29 – march 2, 2024.
2023-11-22 08:00:00 - Press Release
Cue Biopharma To Present At The Jmp Securities Hematology And Oncology Summit
Boston, nov. 22, 2023 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of t cell engagers to selectively modulate tumor-specific t cells, announced today that it will take part in a fireside chat at the jmp securities hematology and oncology summit being held virtually from december 5-6, 2023.
2023-11-07 08:00:00 - Press Release
Cue Biopharma To Present At Three Upcoming Investor Healthcare Conferences In November
Boston, nov. 07, 2023 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of t cell engagers to selectively modulate tumor-specific t cells, announced today that it will participate in three investor conferences this november, the stifel healthcare conference, to be held in new york from november 14-15, the jefferies london healthcare conference, to be held in london from november 14-16, and the piper sandler annual healthcare conference, to be held in new york from november 28-30.
2023-11-03 12:00:00 - Press Release
Cue Biopharma Presents New Positive Data From Phase 1 Trials Of Cue-101 In Head And Neck Cancer And Cue-102 In Wilms' Tumor 1 Positive Cancers At Sitc 2023
Boston, nov. 03, 2023 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of t cell engagers to selectively modulate tumor-specific t cells, announced today the presentation of new positive data from its ongoing fully enrolled phase 1 trials evaluating its lead interleukin-2 (il-2)-based t cell engager, cue-101, as a monotherapy and in combination with keytruda® (pembrolizumab) for patients with recurrent/metastatic hpv+ head and neck squamous cell carcinoma (hnscc). new clinical data will also be reported from the company's ongoing phase 1 trial evaluating its second candidate, cue-102, for the treatment of wilms' tumor 1 positive (wt1+) recurrent/metastatic cancers.
Latest News
2024-04-15 10:55:17 - Zacks Investment Research
Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now
Cue Biopharma (CUE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
2024-04-08 21:43:09 - Seeking Alpha
Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript
Cue Biopharma, Inc. (NASDAQ:CUE ) Q4 2023 Earnings Conference Call April 8, 2024 4:30 PM ET Company Participants Daniel Passeri - CEO Matteo Levisetti - Chief Medical Officer Anish Suri - President & Chief Scientific Officer Kerri-Ann Millar - CFO Conference Call Participants Stephen Willey - Stifel Ren Benjamin - JMP Operator Greetings and welcome to the Cue Biopharma Investor Update call. At this time, all participants are in listen-only mode.
2023-11-22 08:00:00 - GlobeNewsWire
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will take part in a fireside chat at the JMP Securities Hematology and Oncology Summit being held virtually from December 5-6, 2023.
2023-11-11 15:32:08 - Seeking Alpha
Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript
Cue Biopharma, Inc. (NASDAQ:CUE ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Daniel Passeri - CEO Matteo Levisetti - Chief Medical Officer Anish Suri - President & Chief Scientific Officer Kerri-Ann Millar - CFO Conference Call Participants Reni Benjamin - JMP Securities Ted Tenthoff - Piper Sandler Operator Good afternoon, ladies and gentlemen, and welcome to the Cue Biopharma Third Quarter 2023 Earnings Call. At this time, all lines are in listen-only mode.
2023-11-07 08:00:00 - GlobeNewsWire
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will participate in three investor conferences this November, the Stifel Healthcare Conference, to be held in New York from November 14-15, the Jefferies London Healthcare Conference, to be held in London from November 14-16, and the Piper Sandler Annual Healthcare Conference, to be held in New York from November 28-30.
2023-08-09 22:23:03 - Seeking Alpha
Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript
Cue Biopharma, Inc. (NASDAQ:CUE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Dan Passeri - Chief Executive Officer Anish Suri - President & Chief Scientific Officer Matteo Levisetti - Chief Medical Officer Kerri Millar - Chief Financial Officer Conference Call Participants Ted Tenthoff - Piper Sandler Ren Benjamin - JMP Securities Operator Greetings, and welcome to the Cue Biopharma Investor Update Call. At this time, all participants are in a listen-only mode.
2023-06-22 06:40:45 - InvestorPlace
3 Biotech Stocks to Buy as Companies Ink Major Deals
With patent expirations around the corner, some of the biggest pharmaceutical and biotech companies will soon face generic competition, creating a big opportunity for these top biotech stocks to buy. In 2023 alone, pharmaceutical and biotech companies spent about $85 billion on acquisitions.
2023-06-05 08:00:00 - GlobeNewsWire
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that it will present at the Jefferies Global Healthcare Conference being held June 7–9, 2023 in New York.
2023-05-26 06:19:56 - InvestorPlace
3 Biotech Stocks Sitting on Huge-Upside Catalysts
Now is a great time to start accumulating top biotech stocks. The biotech boom is red-hot.
2023-05-08 08:00:00 - GlobeNewsWire
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held at the New York Hilton Midtown, May 15-16, 2023.